Key Points
-
The altered metabolism of arachidonic acid by cyclooxygenase (COX) and lipoxygenase (LOX) is a common feature of several epithelial-derived malignancies and has been shown to have crucial roles in cancer progression.
-
The production of arachidonic acid-derived prostanoids and leukotrienes occurs in single cells or takes place in a complex manner in which these biologically active lipids, specifically leukotrienes, are generated by transcellular biosynthesis through the cooperation of multiple different types of cells in the tumour and inflamed tissues.
-
Pro-inflammatory prostaglandins and leukotrienes promote tumour growth by regulating tumour epithelial cells themselves and orchestrating the complex interactions between transformed epithelial cells and surrounding stromal cells to establish the tumour microenvironment that facilitates tumour-associated angiogenesis and evades attack by the immune system.
-
Prostaglandins and leukotrienes can modulate tumour epithelial cell proliferation, apoptosis, and migration and invasion through multiple signalling pathways in both an autocrine and paracrine fashion.
-
Prostaglandins and leukotrienes are central molecules in the regulation of stem cell homeostasis.
-
Pro-inflammatory prostaglandins and leukotrienes are key mediators in the crosstalk between tumour epithelial cells and their surrounding stromal cells in establishing a tumour microenvironment with chronic inflammation and immunosuppression.
-
Although non-steroidal anti-inflammatory drugs (NSAIDs), which target COX enzymes, are still among the most promising chemopreventive agents for cancer, cardiovascular and gastrointestinal side effects have dampened enthusiasm for their use as chemopreventive agents. Understanding the roles of prostaglandins and leukotrienes in epithelial-derived tumours and their microenvironment may help to develop cancer biomarkers and chemopreventive and/or therapeutic agents with a greater benefit and fewer side effects than NSAIDs.
Abstract
Eicosanoids, including prostaglandins and leukotrienes, are biologically active lipids that have been implicated in various pathological processes, such as inflammation and cancer. This Review highlights our understanding of the intricate roles of eicosanoids in epithelial-derived tumours and their microenvironment. The knowledge of how these lipids orchestrate the complex interactions between transformed epithelial cells and the surrounding stromal cells is crucial for understanding tumour evolution, progression and metastasis. Understanding the molecular mechanisms underlying the role of prostaglandins and other eicosanoids in cancer progression will help to develop more effective cancer chemopreventive and/or therapeutic agents.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nature Med. 10, 789–799 (2004).
Ting, A. H., McGarvey, K. M. & Baylin, S. B. The cancer epigenome — components and functional correlates. Genes Dev. 20, 3215–3231 (2006).
Woutersen, R. A., Appel, M. J., van Garderen-Hoetmer, A. & Wijnands, M. V. Dietary fat and carcinogenesis. Mutat. Res. 443, 111–127 (1999).
Harris, R. E. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17, 55–67 (2009).
Pidgeon, G. P. et al. Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev. 26, 503–524 (2007).
Dubois, R. N. et al. Cyclooxygenase in biology and disease. FASEB J. 12, 1063–1073 (1998).
Eberhart, C. E. et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107, 1183–1188 (1994). This study was the first to report that COX2 expression is increased in human CRC.
de Groot, D. J., de Vries, E. G., Groen, H. J. & de Jong, S. Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit. Rev. Oncol. Hematol. 61, 52–69 (2007).
Gupta, R. A. et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res. 63, 906–911 (2003).
Wang, D. et al. Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6, 285–295 (2004). This report was the first to indicate crosstalk between PGE 2 signalling and Wnt signalling in promoting colon tumour growth.
Wang, D. & DuBois, R. N. Measurement of eicosanoids in cancer tissues. Methods Enzymol. 433, 27–50 (2007).
Folco, G. & Murphy, R. C. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol. Rev. 58, 375–388 (2006).
Zarini, S., Gijon, M. A., Ransome, A. E., Murphy, R. C. & Sala, A. Transcellular biosynthesis of cysteinyl leukotrienes in vivo during mouse peritoneal inflammation. Proc. Natl Acad. Sci. USA 106, 8296–8301 (2009).
Rigas, B., Goldman, I. S. & Levine, L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 122, 518–523 (1993).
Wang, D. & Dubois, R. N. Cyclooxygenase-2: a potential target in breast cancer. Semin. Oncol. 31, 64–73 (2004).
McLemore, T. L. et al. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res. 48, 3140–3147 (1988).
Hambek, M. et al. Inverse correlation between serum PGE2 and T classification in head and neck cancer. Head Neck 29, 244–248 (2007).
Backlund, M. G. et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J. Biol. Chem. 280, 3217–3223 (2005).
Wolf, I. et al. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res. 66, 7818–7823 (2006).
Hughes, D. et al. NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev. Res. (Phila Pa) 1, 241–249 (2008).
Thiel, A. et al. 15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin. Cancer Res. 15, 4572–4580 (2009).
Hansen-Petrik, M. B. et al. Prostaglandin E2 protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in ApcMin/+ mice. Cancer Res. 62, 403–408 (2002).
Yan, M. et al. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc. Natl Acad. Sci. USA 106, 9409–9413 (2009).
Kawamori, T., Uchiya, N., Sugimura, T. & Wakabayashi, K. Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 24, 985–990 (2003).
Myung, S. J. et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc. Natl Acad. Sci. USA 103, 12098–12102 (2006).
Nakanishi, M. et al. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res. 68, 3251–3259 (2008).
Watanabe, K. et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res. 59, 5093–5096 (1999).
Mutoh, M. et al. Involvement of prostaglandin E receptor subtype EP4 in colon carcinogenesis. Cancer Res. 62, 28–32 (2002).
Sonoshita, M. et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcΔ716 knockout mice. Nature Med. 7, 1048–1051 (2001). This report was first to indicate that PGE 2 signalling promotes tumour-associated angiogenesis in vivo .
Oshima, H. et al. Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. Gastroenterology 131, 1086–1095 (2006).
Keith, R. L. et al. Prostaglandin E2 receptor subtype 2 (EP2) null mice are protected against murine lung tumorigenesis. Anticancer Res. 26, 2857–2861 (2006).
Chang, S. H., Ai, Y., Breyer, R. M., Lane, T. F. & Hla, T. The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia. Cancer Res. 65, 4496–4499 (2005).
Kawamori, T. et al. Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP1 antagonist, on breast cancer development. Carcinogenesis 22, 2001–2004 (2001).
Park, J. M. et al. Hematopoietic prostaglandin D synthase suppresses intestinal adenomas in ApcMin/+ mice. Cancer Res. 67, 881–889 (2007).
Sertznig, P., Seifert, M., Tilgen, W. & Reichrath, J. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J. Cell Physiol. 212, 1–12 (2007).
Wolfle, D. Enhancement of carcinogen-induced malignant cell transformation by prostaglandin F2α . Toxicology 188, 139–147 (2003).
Wang, D. et al. Crosstalk between peroxisome proliferator-activated receptor δand VEGF stimulates cancer progression. Proc. Natl Acad. Sci. USA 103, 19069–19074 (2006).
Larre, S. et al. PGE2 and LTB4 tissue levels in benign and cancerous prostates. Prostaglandins Other Lipid Mediat. 87, 14–19 (2008).
Dreyling, K. W. et al. Leukotriene synthesis by human gastrointestinal tissues. Biochim. Biophys. Acta 878, 184–193 (1986).
Hennig, R. et al. 5-Lipoxygenase and leukotriene B4 receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am. J. Pathol. 161, 421–428 (2002).
Yoo, M. H., Song, H., Woo, C. H., Kim, H. & Kim, J. H. Role of the BLT2, a leukotriene B4 receptor, in Ras transformation. Oncogene 23, 9259–9268 (2004).
Chen, X. et al. Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin. J. Natl Cancer Inst. 95, 1053–1061 (2003).
Ohd, J. F. et al. Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 124, 57–70 (2003).
Matsuyama, M. et al. Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis. Oncol. Rep. 18, 99–104 (2007).
Magnusson, C., Ehrnstrom, R., Olsen, J. & Sjolander, A. An increased expression of cysteinyl leukotriene 2 receptor in colorectal adenocarcinomas correlates with high differentiation. Cancer Res. 67, 9190–9198 (2007).
Wang, D., Buchanan, F. G., Wang, H., Dey, S. K. & DuBois, R. N. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res. 65, 1822–1829 (2005).
Castellone, M. D., Teramoto, H., Williams, B. O., Druey, K. M. & Gutkind, J. S. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-β-catenin signaling axis. Science 310, 1504–1510 (2005). This report was the first to show that PGE 2 activates Wnt signalling by the disruption of a β-catenin inhibitory complex.
Krysan, K. et al. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res. 65, 6275–6281 (2005).
Zhou, J. et al. Interactions between prostaglandin E2, liver receptor homologue-1, and aromatase in breast cancer. Cancer Res. 65, 657–663 (2005).
Sheng, H., Shao, J., Morrow, J., Beauchamp, R. D. & DuBois, R. N. Modulation of apoptosis by prostaglandin treatment in human colon cancer cells. Cancer Res. 58, 362–366 (1998).
Poligone, B. & Baldwin, A. S. Positive and negative regulation of NF-κB by COX-2: roles of different prostaglandins. J. Biol. Chem. 276, 38658–38664 (2001).
Sales, K. J., Boddy, S. C., Williams, A. R., Anderson, R. A. & Jabbour, H. N. F-prostanoid receptor regulation of fibroblast growth factor 2 signaling in endometrial adenocarcinoma cells. Endocrinology 148, 3635–3644 (2007).
Kim, J. et al. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res. 65, 6189–6198 (2005).
Jeong, C. H. et al. [6]-gingerol suppresses colon cancer growth by targeting leukotriene A4 hydrolase. Cancer Res. 69, 5584–5591 (2009).
Ihara, A. et al. Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. J. Pharmacol. Sci. 103, 24–32 (2007).
Tong, W. G., Ding, X. Z., Talamonti, M. S., Bell, R. H. & Adrian, T. E. LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochem. Biophys. Res. Commun. 335, 949–956 (2005).
Mezhybovska, M., Wikstrom, K., Ohd, J. F. & Sjolander, A. The inflammatory mediator leukotriene D4 induces β-catenin signaling and its association with antiapoptotic Bcl-2 in intestinal epithelial cells. J. Biol. Chem. 281, 6776–6784 (2006).
Paruchuri, S., Hallberg, B., Juhas, M., Larsson, C. & Sjolander, A. Leukotriene D4 activates MAPK through a Ras-independent but PKCɛ-dependent pathway in intestinal epithelial cells. J. Cell Sci. 115, 1883–1893 (2002).
Ohd, J. F., Wikstrom, K. & Sjolander, A. Leukotrienes induce cell-survival signaling in intestinal epithelial cells. Gastroenterology 119, 1007–1018 (2000).
Paruchuri, S., Mezhybovska, M., Juhas, M. & Sjolander, A. Endogenous production of leukotriene D4 mediates autocrine survival and proliferation via CysLT1 receptor signalling in intestinal epithelial cells. Oncogene 25, 6660–6665 (2006).
Buchanan, F. G., Wang, D., Bargiacchi, F. & DuBois, R. N. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J. Biol. Chem. 278, 35451–35457 (2003).
Buchanan, F. G. et al. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc. Natl Acad. Sci. USA 103, 1492–1497 (2006). This study was the first to report a link between PGE 2 signalling and the metastatic spread of colon tumour cells to the liver in vivo .
Han, C., Michalopoulos, G. K. & Wu, T. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J. Cell Physiol. 207, 261–270 (2006).
Pai, R. et al. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nature Med. 8, 289–293 (2002).
Ito, H. et al. Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res. 64, 7439–7446 (2004).
Pan, M. R., Hou, M. F., Chang, H. C. & Hung., W. C. Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. J. Biol. Chem. 283, 11155–11163 (2008).
Yang, L. et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res. 66, 9665–9672 (2006).
Qualtrough, D. et al. Prostaglandin F2α stimulates motility and invasion in colorectal tumor cells. Int. J. Cancer 121, 734–740 (2007).
Sales, K. J., Boddy, S. C. & Jabbour, H. N. F-prostanoid receptor alters adhesion, morphology and migration of endometrial adenocarcinoma cells. Oncogene 27, 2466–2477 (2008).
Nie, D. et al. Thromboxane A2 receptors in prostate carcinoma: expression and its role in regulating cell motility via small GTPase Rho. Cancer Res. 68, 115–121 (2008).
Hennig, R. et al. LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice. Neoplasia 7, 417–425 (2005).
Paruchuri, S., Broom, O., Dib, K. & Sjolander, A. The pro-inflammatory mediator leukotriene D4 induces phosphatidylinositol 3-kinase and Rac-dependent migration of intestinal epithelial cells. J. Biol. Chem. 280, 13538–13544 (2005).
Liou, J. Y. et al. Cyclooxygenase-2-derived prostaglandin e2 protects mouse embryonic stem cells from apoptosis. Stem Cells 25, 1096–1103 (2007).
North, T. E. et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 447, 1007–1011 (2007). This paper describes the first evidence that PGE 2 can regulate stem and progenitor cell homeostasis.
Goessling, W. et al. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 136, 1136–1147 (2009).
Wada, K. et al. Leukotriene B4 and lipoxin A4 are regulatory signals for neural stem cell proliferation and differentiation. FASEB J. 20, 1785–1792 (2006).
Chung, J. W. et al. Leukotriene B4 pathway regulates the fate of the hematopoietic stem cells. Exp. Mol. Med. 37, 45–50 (2005).
Boehmler, A. M. et al. The CysLT1 ligand leukotriene D4 supports α4β1- and α5β1-mediated adhesion and proliferation of CD34+ hematopoietic progenitor cells. J. Immunol. 182, 6789–6798 (2009).
Braccioni, F. et al. The effect of cysteinyl leukotrienes on growth of eosinophil progenitors from peripheral blood and bone marrow of atopic subjects. J. Allergy Clin. Immunol. 110, 96–101 (2002).
Noonan, D. M., De Lerma Barbaro, A., Vannini, N., Mortara, L. & Albini, A. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev. 27, 31–40 (2008).
Mahida, Y. R. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm. Bowel Dis. 6, 21–33 (2000).
Sheibanie, A. F. et al. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23–IL-17 axis. J. Immunol. 178, 8138–8147 (2007). This was the first study that offered direct evidence that PGE 2 treatment exacerbates inflammation and disease severity in a mouse model of IBD.
Chizzolini, C. et al. Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood 112, 3696–3703 (2008).
Boniface, K. et al. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J. Exp. Med. 206, 535–548 (2009).
Yao, C. et al. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nature Med. 15, 633–640 (2009). This paper showed the first in vivo evidence that EP4 mediates the effects of PGE 2 on promoting chronic inflammation.
Scandella, E., Men, Y., Gillessen, S., Forster, R. & Groettrup, M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 100, 1354–1361 (2002).
Angeli, V. et al. Role of the parasite-derived prostaglandin D2 in the inhibition of epidermal Langerhans cell migration during schistosomiasis infection. J. Exp. Med. 193, 1135–1147 (2001).
Henderson, W. R. Jr. The role of leukotrienes in inflammation. Ann. Intern. Med. 121, 684–697 (1994).
Stanke-Labesque, F., Pofelski, J., Moreau-Gaudry, A., Bessard, G. & Bonaz, B. Urinary leukotriene E4 excretion: a biomarker of inflammatory bowel disease activity. Inflamm Bowel Dis. 14, 769–774 (2008).
Bomalaski, J. S., Dundee, D., Brophy, L. & Clark, M. A. Leukotriene B4 modulates phospholipid methylation and chemotaxis in human polymorphonuclear leukocytes. J. Leukoc. Biol. 47, 1–12 (1990).
Islam, S. A. et al. The leukotriene B4 lipid chemoattractant receptor BLT1 defines antigen-primed T cells in humans. Blood 107, 444–453 (2006).
Shin, E. H., Lee, H. Y. & Bae, Y. S. Leukotriene B4 stimulates human monocyte-derived dendritic cell chemotaxis. Biochem. Biophys. Res. Commun. 348, 606–611 (2006).
Haribabu, B. et al. Targeted disruption of the leukotriene B4 receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J. Exp. Med. 192, 433–438 (2000).
Woo, C. H. et al. Leukotriene B4 stimulates Rac-ERK cascade to generate reactive oxygen species that mediates chemotaxis. J. Biol. Chem. 277, 8572–8578 (2002).
Del Prete, A. et al. Regulation of dendritic cell migration and adaptive immune response by leukotriene B4 receptors: a role for LTB4 in up-regulation of CCR7 expression and function. Blood 109, 626–631 (2007).
Snijdewint, F. G., Kalinski, P., Wierenga, E. A., Bos, J. D. & Kapsenberg, M. L. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J. Immunol. 150, 5321–5329 (1993).
Huang, M. et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 58, 1208–1216 (1998).
Stolina, M. et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 164, 361–370 (2000).
Zeddou, M. et al. Prostaglandin E2 induces the expression of functional inhibitory CD94/NKG2A receptors in human CD8+ T lymphocytes by a cAMP-dependent protein kinase A type I pathway. Biochem. Pharmacol. 70, 714–724 (2005).
Baratelli, F. et al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J. Immunol. 175, 1483–1490 (2005).
Ahmadi, M., Emery, D. C. & Morgan, D. J. Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res. 68, 7520–7529 (2008).
von Bergwelt-Baildon, M. S. et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 108, 228–237 (2006).
Yang, L. et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J. Clin. Invest. 111, 727–735 (2003). This study reported the first in vivo evidence that PGE 2 is a mediator of cancer-associated immunodeficiency.
Goodwin, J. S. & Ceuppens, J. Regulation of the immune response by prostaglandins. J. Clin. Immunol. 3, 295–315 (1983).
Sinha, P., Clements, V. K., Fulton, A. M. & Ostrand-Rosenberg, S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67, 4507–4513 (2007).
Wang, D. et al. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J. Exp. Med. 203, 941–951 (2006).
Battersby, S. et al. Seminal plasma and prostaglandin E2 up-regulate fibroblast growth factor 2 expression in endometrial adenocarcinoma cells via E-series prostanoid-2 receptor-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase pathway. Hum. Reprod. 22, 36–44 (2007).
Chang, S. H. et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc. Natl Acad. Sci. USA 101, 591–596 (2004).
Spinella, F., Rosano, L., Di Castro, V., Natali, P. G. & Bagnato, A. Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J. Biol. Chem. 279, 46700–46705 (2004).
Jain, S., Chakraborty, G., Raja, R., Kale, S. & Kundu, G. C. Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res. 68, 7750–7759 (2008).
Ding, Y. B. et al. PGE2 up-regulates vascular endothelial growth factor expression in MKN28 gastric cancer cells via epidermal growth factor receptor signaling system. Exp. Oncol. 27, 108–113 (2005).
Sales, K. J. et al. A novel angiogenic role for prostaglandin F2α-FP receptor interaction in human endometrial adenocarcinomas. Cancer Res. 65, 7707–7716 (2005).
Wallace, A. E. et al. Prostaglandin F2α-F-prostanoid receptor signaling promotes neutrophil chemotaxis via chemokine (C-X-C motif) ligand 1 in endometrial adenocarcinoma. Cancer Res. 69, 5726–5733 (2009).
Nozawa, H., Chiu, C. & Hanahan, D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl Acad. Sci. USA 103, 12493–12498 (2006).
Pradono, P. et al. Gene transfer of thromboxane A2 synthase and prostaglandin I2 synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res. 62, 63–66 (2002).
Kamiyama, M. et al. EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene 25, 7019–7028 (2006).
Amano, H. et al. Host prostaglandin E2-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J. Exp. Med. 197, 221–232 (2003).
Pai, R. et al. PGE2 stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem. Biophys. Res. Commun. 286, 923–928 (2001).
Dormond, O., Bezzi, M., Mariotti, A. & Ruegg, C. Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. J. Biol. Chem. 277, 45838–45846 (2002).
Salcedo, R. et al. Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood 102, 1966–1977 (2003).
Daniel, T. O., Liu, H., Morrow, J. D., Crews, B. C. & Marnett, L. J. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res. 59, 4574–4577 (1999).
Murata, T. et al. Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo. Proc. Natl Acad. Sci. USA 105, 20009–20014 (2008). This was the first report to show that PGD 2 –DP signalling inhibits tumour-associated angiogenesis and tumour growth in vivo.
Kim, G. Y., Lee, J. W., Cho, S. H., Seo, J. M. & Kim, J. H. Role of the low-affinity leukotriene B4 receptor BLT2 in VEGF-induced angiogenesis. Arterioscler Thromb. Vasc. Biol. 29, 915–920 (2009).
Modat, G., Muller, A., Mary, A., Gregoire, C. & Bonne, C. Differential effects of leukotrienes B4 and C4 on bovine aortic endothelial cell proliferation in vitro. Prostaglandins 33, 531–538 (1987).
Tsopanoglou, N. E., Pipili-Synetos, E. & Maragoudakis, M. E. Leukotrienes C4 and D4 promote angiogenesis via a receptor-mediated interaction. Eur. J. Pharmacol. 258, 151–154 (1994).
Steiner, D. R., Gonzalez, N. C. & Wood, J. G. Leukotriene B4 promotes reactive oxidant generation and leukocyte adherence during acute hypoxia. J. Appl. Physiol. 91, 1160–1167 (2001).
Abdel-Majid, R. M. & Marshall, J. S. Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells. J. Immunol. 172, 1227–1236 (2004).
Nakayama, T., Mutsuga, N., Yao, L. & Tosato, G. Prostaglandin E2 promotes degranulation-independent release of MCP-1 from mast cells. J. Leukoc. Biol. 79, 95–104 (2006).
Soria, G. & Ben-Baruch, A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 267, 271–285 (2008).
Salcedo, R. et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96, 34–40 (2000).
Tanaka, S. et al. Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma. Gut 55, 54–61 (2006).
Lin, E. Y. & Pollard, J. W. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 67, 5064–5066 (2007).
Rosengren, S., Olofsson, A. M., von Andrian, U. H., Lundgren-Akerlund, E. & Arfors, K. E. Leukotriene B4-induced neutrophil-mediated endothelial leakage in vitro and in vivo. J. Appl. Physiol. 71, 1322–1330 (1991).
Kanaoka, Y., Maekawa, A., Penrose, J. F., Austen, K. F. & Lam, B. K. Attenuated zymosan-induced peritoneal vascular permeability and IgE-dependent passive cutaneous anaphylaxis in mice lacking leukotriene C4 synthase. J. Biol. Chem. 276, 22608–22613 (2001).
Chan, A. T., Ogino, S. & Fuchs, C. S. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 356, 2131–2142 (2007). This paper reported the first clinical evidence that aspirin seems to reduce the risk of CRCs that overexpress COX2 but not the risk of CRCs with weak or absent expression of COX2.
Chan, A. T., Ogino, S. & Fuchs, C. S. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302, 649–658 (2009). This paper was the first to provide clinical evidence that aspirin can be used to treat advanced CRC.
Cuzick, J. et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 10, 501–507 (2009).
Fitzgerald, G. A. Coxibs and cardiovascular disease. N. Engl. J. Med. 351, 1709–1711 (2004).
Narasimha, A. et al. A novel anti-atherogenic role for COX-2 — potential mechanism for the cardiovascular side effects of COX-2 inhibitors. Prostaglandins Other Lipid Mediat. 84, 24–33 (2007).
Piazuelo, E. et al. Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus. Prostaglandins Other Lipid Mediat. 81, 150–161 (2006).
Rioux, N. & Castonguay, A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis 19, 1393–1400 (1998).
Barry, M. et al. Neoplasms escape selective COX-2 inhibition in an animal model of breast cancer. Ir. J. Med. Sci. 178, 201–208 (2009).
Fegn, L. & Wang, Z. Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2. J. Laryngol. Otol. 123, 880–884 (2009).
Ye, Y. N. et al. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 26, 827–834 (2005).
Chen, X. et al. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin. Cancer Res. 10, 6703–6709 (2004).
Wenger, F. A. et al. Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters. Clin. Exp. Metastasis 19, 681–687 (2002).
Hennig, R. et al. Effect of LY293111 in combination with gemcitabine in colonic cancer. Cancer Lett. 210, 41–46 (2004).
Adrian, T. E., Hennig, R., Friess, H. & Ding, X. The role of PPARγ receptors and leukotriene B4 receptors in mediating the effects of LY293111 in pancreatic cancer. PPAR Res. 27 Jan 2009 (doi:10.1155/2008/827096)
Gunning, W. T., Kramer, P. M., Steele, V. E. & Pereira, M. A. Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res. 62, 4199–4201 (2002).
Monzon, F. A. et al. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch. Pathol. Lab. Med. 133, 1600–1606 (2009).
Acknowledgements
This work is partly supportedby the US National Institutes of Health Grants RO1DK 62112, P01-CA-77839, R37-DK47297 and P30 DK-58404 (R.N.D.). R.N.D. (R37-DK47297) is recipient of an NIH MERIT award. We also thank the National Colorectal Cancer Research Alliance (NCCRA) for generous support (R.N.D.). We also kindly thank D. Menter for his assistance in the preparation of figures.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Glossary
- Cysteinyl leukotriene (CysLT)
-
Leukotriene that contains the amino acid cysteine conjugated to the lipid backbone.
- ApcMin/+ mice
-
Carry a point mutation in one Apc allele and spontaneously develop intestinal adenomas. Used as a model for human familial adenomatous polyposis and for human sporadic colorectal cancer.
- Azoxymethane (AOM) mouse model
-
One of the chemically induced colorectal cancer models in which mice are exposed to a chemical carcinogen, AOM.
- T helper 17 (TH17) cells
-
A functional subset of CD4+ T helper cells that secrete particular inflammatory cytokines, including interleukin-17, which mediate pathogenic responses in autoimmune diseases.
- Dendritic cells
-
Bone marrow-derived immune accessory cells that function as antigen-presenting cells for naive T cells and that lead to the initiation of adaptive immune responses to protein antigens.
- Cytotoxic T cells
-
A subgroup of T cells (also known as CD8+ T cells or killer T cells) that are capable of recognizing and inducing the death of infected somatic or tumour cells. CD8+ T cells are recognized as cytotoxic T cells once they become activated.
- Regulatory T cells
-
A T cell subpopulation that suppresses activation of other T cells and maintains immune system homeostasis and peripheral tolerance to self-antigens.
- Myeloid-derived suppressor cells (MDSCs)
-
Immature myeloid cells with potent immunosuppressive functions.
- Cross-presentation
-
A mechanism by which a professional antigen-presenting cell takes up, processes and presents extracellular antigens from a third cell (for example, a virus-infected or tumour cell) with major histocompatibility complex class I molecules to activate a naive CD8+ T cell.
- T cell tolerance
-
Unresponsiveness of the adaptive immune system to antigens, as a result of the inactivation or death of antigen-specific T cells, which is induced by exposure to the antigens.
- ApcΔ716 mice
-
Generated by inserting neomycin into exon 15 of Apc, which results in truncated APC at codon 716. Spontaneously develop intestinal adenomas and are another model for human familial adenomatous polyposis and sporadic colorectal cancer.
- Chick chorioallantoic membrane system
-
A biological assay using the well-vascularized chorioallantoic membrane of the chicken egg to evaluate the biological activity of pro-angiogenic and anti-angiogenic factors.
Rights and permissions
About this article
Cite this article
Wang, D., DuBois, R. Eicosanoids and cancer. Nat Rev Cancer 10, 181–193 (2010). https://doi.org/10.1038/nrc2809
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc2809
This article is cited by
-
S1PR1/S1PR3-YAP signaling and S1P-ALOX15 signaling contribute to an aggressive behavior in obesity-lymphoma
Journal of Experimental & Clinical Cancer Research (2023)
-
Decreased cyclooxygenase-2 associated with impaired megakaryopoiesis and thrombopoiesis in primary immune thrombocytopenia
Journal of Translational Medicine (2023)
-
Key regulator PNPLA8 drives phospholipid reprogramming induced proliferation and migration in triple-negative breast cancer
Breast Cancer Research (2023)
-
In vivo imaging of inflammatory response in cancer research
Inflammation and Regeneration (2023)
-
COX-2/PGE2 upregulation contributes to the chromosome 17p-deleted lymphoma
Oncogenesis (2023)